IL183321A0 - Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof - Google Patents

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Info

Publication number
IL183321A0
IL183321A0 IL183321A IL18332107A IL183321A0 IL 183321 A0 IL183321 A0 IL 183321A0 IL 183321 A IL183321 A IL 183321A IL 18332107 A IL18332107 A IL 18332107A IL 183321 A0 IL183321 A0 IL 183321A0
Authority
IL
Israel
Prior art keywords
receptor
chromanylurea
compounds
inhibit vanilloid
subtype
Prior art date
Application number
IL183321A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL183321A0 publication Critical patent/IL183321A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL183321A 2004-11-24 2007-05-20 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof IL183321A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63063604P 2004-11-24 2004-11-24
PCT/US2005/042545 WO2006065484A2 (en) 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Publications (1)

Publication Number Publication Date
IL183321A0 true IL183321A0 (en) 2008-04-13

Family

ID=36588346

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183321A IL183321A0 (en) 2004-11-24 2007-05-20 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Country Status (13)

Country Link
US (2) US7812019B2 (enExample)
EP (2) EP2527339A1 (enExample)
JP (2) JP4932730B2 (enExample)
KR (2) KR20120137420A (enExample)
CN (2) CN101443327A (enExample)
AU (1) AU2005316972B2 (enExample)
BR (1) BRPI0518581A2 (enExample)
CA (1) CA2588909A1 (enExample)
IL (1) IL183321A0 (enExample)
MX (1) MX2007006205A (enExample)
NZ (1) NZ555318A (enExample)
TW (1) TW200633712A (enExample)
WO (1) WO2006065484A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086331A2 (en) * 2004-03-02 2005-09-15 Rosemount, Inc. Process device with improved power generation
US8538560B2 (en) 2004-04-29 2013-09-17 Rosemount Inc. Wireless power and communication unit for process field devices
US8145180B2 (en) * 2004-05-21 2012-03-27 Rosemount Inc. Power generation for process devices
JP4932730B2 (ja) * 2004-11-24 2012-05-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
RU2007139541A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
EP1957464A1 (en) * 2005-10-28 2008-08-20 Abbott Laboratories INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
MY144307A (en) * 2006-04-18 2011-08-29 Abbott Lab Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
US7913566B2 (en) 2006-05-23 2011-03-29 Rosemount Inc. Industrial process device utilizing magnetic induction
WO2008059339A2 (en) * 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
US8030504B2 (en) * 2006-12-20 2011-10-04 Abbott Laboratories Antagonists of the TRPV1 receptor and uses thereof
WO2008110863A1 (en) * 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
CL2008003749A1 (es) 2007-12-17 2010-01-15 Janssen Pharmaceutica Nv Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras.
WO2009095726A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Acrylamide derivatives as vanilloid receptor 1 modulators
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
US8250924B2 (en) 2008-04-22 2012-08-28 Rosemount Inc. Industrial process device utilizing piezoelectric transducer
US8694060B2 (en) 2008-06-17 2014-04-08 Rosemount Inc. Form factor and electromagnetic interference protection for process device wireless adapters
CA2726707C (en) 2008-06-17 2016-01-19 Rosemount Inc. Rf adapter for field device with low voltage intrinsic safety clamping
JP5255698B2 (ja) * 2008-06-17 2013-08-07 ローズマウント インコーポレイテッド 電圧降下が可変のフィールド機器用無線アダプタ
US8929948B2 (en) 2008-06-17 2015-01-06 Rosemount Inc. Wireless communication adapter for field devices
WO2010023512A1 (en) * 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
MX2011004090A (es) * 2008-10-17 2011-05-31 Abbott Lab Antagonistas trpv1.
JP2012505907A (ja) * 2008-10-17 2012-03-08 アボット・ラボラトリーズ Ｔｒｐｖ１拮抗薬
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN101654435B (zh) * 2009-06-09 2014-01-29 沈阳药科大学 N-苯甲基喹啉羧酸类化合物、组合物及其制备方法
US20100318007A1 (en) * 2009-06-10 2010-12-16 O'brien Donald J Electromechanical tactile stimulation devices and methods
US9674976B2 (en) 2009-06-16 2017-06-06 Rosemount Inc. Wireless process communication adapter with improved encapsulation
US8626087B2 (en) 2009-06-16 2014-01-07 Rosemount Inc. Wire harness for field devices used in a hazardous locations
CN102066372B (zh) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
US10761524B2 (en) 2010-08-12 2020-09-01 Rosemount Inc. Wireless adapter with process diagnostics
UY33966A (es) 2011-03-25 2012-10-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
US9310794B2 (en) 2011-10-27 2016-04-12 Rosemount Inc. Power supply for industrial process field device
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
CN109574972A (zh) * 2018-07-13 2019-04-05 郑州大学 一种3-烷基取代-4-色满酮类化合物及其制备方法
PE20240017A1 (es) * 2020-09-30 2024-01-04 Univ Leuven Kath Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer
WO2025161263A1 (zh) * 2024-01-31 2025-08-07 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029668T2 (de) * 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
NL8900565A (nl) 1989-03-08 1990-10-01 Philips Nv Methode voor de verwerking van een radio data signaal, alsmede ontvanger voor de uitvoering van deze methode.
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
CA2264020A1 (en) * 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
CA2389360C (en) 1999-11-16 2008-06-03 Steffen Breitfelder Urea derivatives as anti-inflammatory agents
WO2003097586A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
US7514562B2 (en) * 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
JP4932730B2 (ja) * 2004-11-24 2012-05-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用
EP1957464A1 (en) * 2005-10-28 2008-08-20 Abbott Laboratories INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR

Also Published As

Publication number Publication date
JP2012111766A (ja) 2012-06-14
NZ555318A (en) 2011-01-28
AU2005316972A1 (en) 2006-06-22
TW200633712A (en) 2006-10-01
US20060128689A1 (en) 2006-06-15
EP2527339A1 (en) 2012-11-28
KR20070086607A (ko) 2007-08-27
AU2005316972B2 (en) 2011-11-10
KR20120137420A (ko) 2012-12-20
CA2588909A1 (en) 2006-06-22
CN101443327A (zh) 2009-05-27
CN102161653A (zh) 2011-08-24
JP4932730B2 (ja) 2012-05-16
US7812019B2 (en) 2010-10-12
WO2006065484A2 (en) 2006-06-22
BRPI0518581A2 (pt) 2008-11-25
EP1844038A2 (en) 2007-10-17
KR101250824B1 (ko) 2013-04-05
WO2006065484A3 (en) 2009-02-19
MX2007006205A (es) 2009-02-13
US20110152250A1 (en) 2011-06-23
US8440691B2 (en) 2013-05-14
JP2008532925A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
IL183321A0 (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
ZA200808691B (en) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
AP1916A (en) Purine compounds and use thereof as cannabinoid receptor ligands
EP1773871A4 (en) COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES
ZA200606313B (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
IL192426A0 (en) Prokineticin 2 receptor antagonists
IL192424A0 (en) Prokineticin 1 receptor antagonists
EP1814550A4 (en) ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1
ZA200710169B (en) Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists
DK1463759T3 (da) Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
IL179462A0 (en) Use of the receptor gpr86
EP2012779A4 (en) PROCESS FOR PREPARING INDAZOLYL UREES THAT INHIBIT VANILLOID RECEPTORS OF SUBTYPE 1 (VR1)
HK1111688A (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
EP1723145A4 (en) SUBSTITUTED 5,12-DIAZENZOANTHRACENANALOGA
ZA200705114B (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
EP1967519A4 (en) 3,4-DIHYDROBENZOXAZINE COMPOUND AND VANNILLLOID RECEPTOR 1 ACTIVITY INHIBITORS
GB0403791D0 (en) 'Kwicap'
IL179980A0 (en) Asymmetrically substituted biaryldiphosphine ligands 1
IL179981A0 (en) Asymmetrically substituted biaryldiphosphine ligands 111
HK1121956A (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
AU2003300867A8 (en) Uses of the snorf207 receptor
IL173515A0 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
AU2003278113A8 (en) Stabilising agent mixture
ZA200804716B (en) 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (VR1) activity
HK1093728A (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor